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Objectives: Biomarkers are useful for establishing disease severity or prognosis in patients with chronic
kidney disease. The aim of our study was to determine the plasma concentrations of novel cardiovascular
biomarkers in patients on chronic hemodialysis in the context of published upper reference limits (URL)
of these biomarkers; and to compare the plasma concentrations of those same analytes before and after
hemodialysis session.
Design and methods: Plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP),
mid-regional pro-A-type natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM),
C-terminal pro-endothelin-1 (CT-proET-1), C-terminal pro-arginine vasopressin (CT-proAVP, also known as
Copeptin) and soluble ST2 (sST2) were measured in 28 patients before and after dialysis session. Of the 28
patients with conventional hemodialysis, 24 had low-ﬂux hemoﬁltration and 4 had high-ﬂux hemodiaﬁltration.
Results: Median plasma concentrations of the biomarkers obtained before hemodialysis were as follows:
NT-proBNP, 11,307 ng/L (URL, 500 ng/L); MR-proANP, 778 pmol/L (URL, 250 pmol/L); MR-proADM,
2.57 nmol/L (URL, 0.52 nmol/L); median CT-proET-1, 252 pmol/L (URL, 75 pmol/L); median CT-proAVP,
142 pmol/L (URL, 19 pmol/L); and median sST2, 27 ng/mL (URL, 50 ng/mL). Median relative analyte
changes after low-ﬂux vs. high-ﬂux dialysis compared to predialysis values were +19% vs. −43%
for NT-proBNP; +7% vs. −45% for MR-proANP; −2% vs. −63% for MR-proADM; −19% vs. −61% for
CT-proET-1; +13% vs. −64% for CT-proAVP; and +2% vs. +3% for sST2.
Conclusions: Plasma concentrations of the investigated biomarkers were markedly increased in
chronic hemodialysis patients (with the exception of sST2). After hemodialysis session, analyte concentra-
tions (with the exception of sST2) decreased signiﬁcantly using a high-ﬂux membrane but not if using a
low-ﬂux membrane.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Both, chronic kidney disease and hemodialysis itself can lead to
cardiovascular alterations such as atherosclerosis and cardiac struc-
tural and functional abnormalities. Even though the quality and efﬁ-
cacy of hemodialysis therapy have greatly improved in recent years,
cardiovascular disease remains the leading cause of death in
hemodialysis patients. In this context, measurement of biomarkers
might be useful for establishing disease severity or prognosis in
patients with chronic hemodialysis.ry Medicine, Konventhospital
ria.
).
ty of Clinical Chemists. PublishedSeveral biomarkers have been widely used in cardiac disease.
Among them, N-terminal pro-B-type natriuretic peptide (NT-proBNP),
mid-regional pro-A-type natriuretic peptide (MR-proANP), mid-regional
pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1
(CT-proET-1), C-terminal pro-arginine vasopressin (CT-proAVP,
also known as Copeptin) and soluble ST2 (sST2) gained special interest
in acute coronary syndrome and in heart failure.
In chronic hemodialysis, there are substantial differences in
membrane composition and structure between low-ﬂux and high-ﬂux
dialysers [1]. A categorization based primarily on solute permeability
properties is based on the size of molecules being passed through by
low-ﬂux membranes (molecular weight [MW] b 5000 Da) and high-
ﬂux membranes (MW b 35,000 Da). The goal of high-ﬂux membranes
is to pass relatively large molecules such as beta-2-microglobulin
(MW ~11,600 Da), but not to pass e.g., albumin (MW ~66,400 Da) or
immunoglobulin G (MW ~140,000 Da).by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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point (IEP) 8.45), MR-proANP (38 aa; MW 4018.4 Da; IEP 6.66),
MR-proADM (48 aa; MW, 5114.7 Da, IEP 8.59), CT-proET-1
(45 aa; MW 5448.0 Da; IEP 10.92) and CT-proAVP (39 aa; MW
4021.4 Da, IEP 4.11) are small peptide fragments that are excised from
larger precursor peptides during posttranslational processing, and
they share a low MW [2–9]. In contrast, the protein sST2 has 328 aa
and a MW of 36,993 Da [http://www.uniprot.org/uniprot/Q01638].
It is described in the literature that NT-proBNP, CT-proAVP and sST2
are (partly) glycosylated [http://www.uniprot.org/uniprot/P16860,
http://www.uniprot.org/uniprot/P01185, http://www.uniprot.org/
uniprot/Q01638], whereas we are not aware on any information that
MR-proANP, MR-proADM or CT-proET-1 are glycosylated as well.
Based on these considerations, we hypothesized that NT-proBNP, MR-
proANP, MR-proADM, CT-proET-1, CT-proAVP and sST2 would exhibit
different behaviors in time course in low-ﬂux vs. high-ﬂux dialysis.
Hence, the aims of this study were (1) to determine the plasma con-
centrations of novel cardiovascular biomarkers in patients on chronic
hemodialysis in the context of published upper reference limits (URL)
of these biomarkers; and (2) to compare the plasma concentrations of
those same analytes before and after hemodialysis session in low-ﬂux
vs. high-ﬂux dialysis.
2. Patients and methods
This single center observational study was performed at the dialysis
unit of the Department of Internal Medicine at the Hospital Bad Ischl,
Austria. The study was approved by the local ethics committee in
accordance to the Declaration of Helsinki. All patients on chronic
hemodialysis with a hemodialysis session between October 1 and
December 31, 2007were included after informed consentwas obtained.
Each patient was included only once during the study period.
Conventional hemodialysis was performed with the instrument
used routinely during the study period (Fresenius Option 4008H Type
4008E, Fresenius Medical Care, Germany). Low-ﬂux hemoﬁltration
was performed with a Fresenius Polysulfone® membrane (Fresenius
Polysulfone® Low-Flux Dialyser F8HPS, Fresenius Medical Care,
Germany), and high-ﬂux hemodiaﬁltration was performed with a
Gambro Polyﬂux® H membrane (Gambro Polyﬂux® 170 H, Gambro
Dialysatoren, Germany). As the present evaluation was intended
as a real-life study reﬂecting clinical routine care, the choice of
hemodialysis modalities for each patient was at the discretion of
the treating physician.
The supplementary material to the methods section details the
methods of biomarker measurement and the statistical analysis.
3. Results and discussion
3.1. Patient characteristics and hemodialysis modalities
During the study period, 28 patients (18 male and 10 female) were
on chronic hemodialysis at the study center; the median age was
69 years (range, 44–84). The comprehensive patient characteristics
are shown in the supplementary material to the results section.
All 28 patients were functionally anephric (deﬁned as urine
output b 250 mL per day).
Of the 28 study participants with conventional hemodialysis, 24 had
low-ﬂux hemoﬁltration and 4 had high-ﬂux hemodiaﬁltration. The
median duration of the dialysis session was 3.9 h (range, 3.0–4.6). The
median blood ﬂow rate was 300 mL/min (range, 200–320). Of the 24
patients with low-ﬂux hemoﬁltration, one patient had a dialysate ﬂow
rate of 500 mL/min and the remaining 23 patients had a dialysate ﬂow
rate of 800 mL/min. All 4 patients with high-ﬂux hemoﬁltration had a
dialysate ﬂow rate of 800 mL/min. The median ultraﬁltrate goal was
2400 mL (range, 400–4500). The median body weight before dialysis
session was 76.0 kg (range, 45.6–106.4), and after dialysis session itwas 73.3 kg (range, 44.4–102.1); this corresponds to a median body
weight reduction of 2.2 kg (range, 0.4–4.3) as a consequence of the
respective dialysis session.
3.2. Biomarker concentrations obtained before hemodialysis session
In the overall cohort of 28 chronic hemodialysis patients with
multiple comorbidities, plasma concentrations of the investigated
biomarkers obtained before the hemodialysis session were as follows:
median NT-proBNP, 11,307 ng/L (range, 398–70,000); median MR-ANP,
778 pmol/L (range, 222–1446); median MR-proADM, 2.57 nmol/L
(range, 1.12–4.02); median CT-proET-1, 252 pmol/L (range, 73–490);
median CT-proAVP, 142 pmol/L (range, 23–270); and median sST2,
27 ng/mL (range, 14–55).
The information in the package insert and published reference value
studies [10,11] indicate that the median circulating concentration of
NT-proBNP is usually b80 ng/L and that the URL is usually b500 ng/L
in healthy populations or in population based samples. Median concen-
trations of MR-proANP are considered to be b45 pmol/L in healthy indi-
viduals and the URL is b250 pmol/L [4,5]. A reference value study on
healthy blood donors and a population-based cohort revealed a median
MR-proADM concentration b0.45 nmol/L and an URL of ~0.52 nmol/L
[6,7]. The information given in the package insert and a published
study on blood donors [8] refer to a median CT-proET-1 plasma
concentration b 47 pmol/L in healthy individuals and an URL b 75
pmol/L. In the package insert and in one published study [9], median
concentrations of CT-proAVP are considered to be b8 pmol/L in healthy
individuals and the URL has been reported to be b19 pmol/L. Notably,
for the analyte sST2 sex-speciﬁc reference values are appropriate with
the URL being considerably higher in men than in women [12–14].
Nevertheless, in studies on blood donors and in population based
samples, median sST2 plasma concentrations are generally b25 ng/mL,
and URL is steadily b50 ng/mL [12–14].
Thus, NT-proBNP, MR-proANP, MR-proADM, CT-proET-1 and
CT-proAVP were consistently increased in chronic hemodialysis in our
study. Reasons for these biomarker elevations are most probably
coexisting atherosclerosis and/or inﬂammation as well as volume
overload and/or cardiac structural and functional abnormalities,
all known to be associated with chronic kidney disease and dialysis
itself. In contrast, there is only low-grade sST2 elevation – if any – in
chronic hemodialysis.
3.3. Biomarker concentrations before and after hemodialysis session
In Table 1, the absolute and relative changes of biomarker plasma
concentrations measured before and after hemodialysis session are
detailed according to the dialysis modalities. The median reduction
ratios were−0.19 in low-ﬂux dialysis vs. +0.43 in high ﬂux dialysis
for NT-proBNP; −0.07 vs. +0.45 for MR-proANP; +0.02 vs. +0.63
for MR-proADM; +0.19 vs. +0.61 for CT-proET-1; −0.13 vs. +0.64
for CT-proAVP; and −0.02 vs. −0.03 for sST2. In Fig. 1, the situation
of relative analyte changes caused by hemodialysis is depicted in detail.
In our study, NT-proBNP (MW ~8500 Da) accumulated after low-
ﬂux dialysis but decreased by ~40% after high-ﬂux dialysis in our
study. Similarly, the middle sized molecules MR-proANP, MR-proADM,
CT-proET-1 and CT-proAVP (MW ~4000–5500 Da) decreased signiﬁ-
cantly by ~45–65% if a high-ﬂux membrane was used but did not
decrease signiﬁcantly if a low-ﬂux dialysator was utilized. Merely,
plasma concentrations of CT-proET-1 decreased by 19% in low-ﬂux
dialysis. It is of course speculative, but in case of CT-proET-1 in
low-ﬂux hemodialysis there might be adhesion of the molecule to
the hemoﬁlter. In contrast, the protein sST2 has MW of ~37,000 Da.
Therefore, sST2 did not pass even a high-ﬂux membrane. The variation
of the analyte sST2 was less than 5% before vs. after dialysis session
regardless of whether a low-ﬂux or high-ﬂux dialysator was used.
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Table 1
Effect of hemodialysis modalities on biomarkers — comparison of plasma concentrations before vs. after dialysis.
Biomarker Biomarkers' molecular weight Low-ﬂux dialysis membrane (24 patients) High-ﬂux dialysis membrane (4 patients)
Before dialysisa After dialysisa After dialysisb Before dialysisa After dialysisa After dialysisb
Albumin ~66,400 Da 355 g/L (206–398) 402 g/L (214–502) 111% (88–139) 354 g/L (293–411) 404 g/L (306–440) 107% (104–120)
IgG ~140,000 Da 10.55 g/L (6.72–14.50) 11.55 g/L (6.63–15.60) 109% (89–142) 11.20 g/L (5.67–20.80) 11.90 g/L (6.98–21.20) 106% (102–123)
NT-proBNP 8457.4 Da 11,191 ng/L (398–70,000) 12,891 ng/L (467–70,000) 119% (88–161)⁎ 12,637 ng/L (1788–35,024) 7740 ng/L (1020–19,802) 57% (55–71)⁎
MR-proANP 4018.4 Da 737 pmol/L (222–1446) 796 pmol/L (196–1615) 107% (88–129)⁎ 898 pmol/L (548–1194) 562 pmol/L (274–668) 55% (50–73)⁎
MR-proADM 5114.7 Da 2.57 nmol/L (1.12–3.55) 2.53 nmol/L (0.89–3.66) 98% (79–117)‡ 2.49 nmol/L (1.71–4.02) 0.80 nmol/L (0.66–1.64) 37% (29–41)⁎
CT-proET-1 5448.0 Da 251 pmol/L (73–349) 201 pmol/L (68–308) 81% (72–96)⁎ 256 pmol/L (204–490) 93 pmol/L (76–218) 39% (30–48)⁎
CT-proAVP 4021.4 Da 142 pmol/L (23–270) 178 pmol/L (19–375) 113% (54–155)⁎ 139 pmol/L (96–182) 46 pmol/L (32–74) 36% (26–41)⁎
sST2 36,993 Da 27 ng/mL (14–43) 27 ng/mL (14–44) 102% (88–118)‡ 28 ng/mL (20–55) 30 ng/mL (21–52) 103% (95–107)‡
Abbreviations: CT-proAVP, C-terminal pro-arginine vasopressin; CT-proET-1, C-terminal pro-endothelin-1; Da, Dalton; IgG, immunoglobulin G; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-A-type natriuretic
peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide, sST2, soluble ST2.
Differences of plasma concentrations of NT-proBNP, MR-proANP, MR-proADM, CT-proET-1, CT-proAVP and sST2, respectively, before and after dialysis session were calculated with two-sided paired t-tests (p-values were not corrected for multiple
comparisons).
⁎ p b 0.005.
‡ p N 0.05.
a Biomarker concentrations before and after dialysis are displayed as actual values according to the units stated. Data are given as median (range).
b Biomarker concentrations before dialysis were set to 100% in each patient, and biomarker concentrations after dialysis are displayed relative to the concentrations before dialysis in percent. Data are given as median (range).
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1166 T. Mueller et al. / Clinical Biochemistry 48 (2015) 1163–1166task. Therefore, it is necessary to know how each biomarker changes in
time course in the setting of conventional hemodialysis for diagnostic
and prognostic purposes. These considerationsmight have implications
on long-term outcome prediction in the setting of chronic kidney
disease and hemodialysis.
3.4. Conclusions
According to the study objectives, the main ﬁndings of this
observational investigation were: (1) plasma concentrations of the
investigated biomarkers were increased in chronic hemodialysis
patients (with the exception of sST2); and (2) after hemodialysis
session, analyte concentrations (with the exception of sST2)
decreased signiﬁcantly using a high-ﬂux membrane but not if
using a low-ﬂux membrane.
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